Interaction of mental comorbidity and physical multimorbidity predicts length-of-stay in medical inpatients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 08 02 2023
accepted: 30 05 2023
medline: 26 6 2023
pubmed: 22 6 2023
entrez: 22 6 2023
Statut: epublish

Résumé

Mental comorbidities of physically ill patients lead to higher morbidity, mortality, health-care utilization and costs. The aim of the study was to investigate the impact of mental comorbidity and physical multimorbidity on the length-of-stay in medical inpatients at a maximum-care university hospital. The study follows a retrospective, quantitative cross-sectional analysis approach to investigate mental comorbidity and physical multimorbidity in internal medicine patients. The study comprised a total of n = 28.553 inpatients treated in 2017, 2018 and 2019 at a German Medical University Hospital. Inpatients with a mental comorbidity showed a median length-of-stay of eight days that was two days longer compared to inpatients without a mental comorbidity. Neurotic and somatoform disorders (ICD-10 F4), behavioral syndromes (F5) and organic disorders (F0) were leading with respect to length-of-stay, followed by affective disorders (F3), schizophrenia and delusional disorders (F2), and substance use (F1), all above the sample mean length-of-stay. The impact of mental comorbidity on length-of-stay was greatest for middle-aged patients. Mental comorbidity and Elixhauser score as a measure for physical multimorbidity showed a significant interaction effect indicating that the impact of mental comorbidity on length-of-stay was greater in patients with higher Elixhauser scores. The findings provide new insights in medical inpatients how mental comorbidity and physical multimorbidity interact with respect to length-of-stay. Mental comorbidity had a large effect on length-of-stay, especially in patients with high levels of physical multimorbidity. Thus, there is an urgent need for new service models to especially care for multimorbid inpatients with mental comorbidity.

Sections du résumé

BACKGROUND
Mental comorbidities of physically ill patients lead to higher morbidity, mortality, health-care utilization and costs.
OBJECTIVE
The aim of the study was to investigate the impact of mental comorbidity and physical multimorbidity on the length-of-stay in medical inpatients at a maximum-care university hospital.
DESIGN
The study follows a retrospective, quantitative cross-sectional analysis approach to investigate mental comorbidity and physical multimorbidity in internal medicine patients.
PATIENTS
The study comprised a total of n = 28.553 inpatients treated in 2017, 2018 and 2019 at a German Medical University Hospital.
MAIN MEASURES
Inpatients with a mental comorbidity showed a median length-of-stay of eight days that was two days longer compared to inpatients without a mental comorbidity. Neurotic and somatoform disorders (ICD-10 F4), behavioral syndromes (F5) and organic disorders (F0) were leading with respect to length-of-stay, followed by affective disorders (F3), schizophrenia and delusional disorders (F2), and substance use (F1), all above the sample mean length-of-stay. The impact of mental comorbidity on length-of-stay was greatest for middle-aged patients. Mental comorbidity and Elixhauser score as a measure for physical multimorbidity showed a significant interaction effect indicating that the impact of mental comorbidity on length-of-stay was greater in patients with higher Elixhauser scores.
CONCLUSIONS
The findings provide new insights in medical inpatients how mental comorbidity and physical multimorbidity interact with respect to length-of-stay. Mental comorbidity had a large effect on length-of-stay, especially in patients with high levels of physical multimorbidity. Thus, there is an urgent need for new service models to especially care for multimorbid inpatients with mental comorbidity.

Identifiants

pubmed: 37347745
doi: 10.1371/journal.pone.0287234
pii: PONE-D-23-03643
pmc: PMC10287009
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0287234

Informations de copyright

Copyright: © 2023 Stahl-Toyota et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Heart Fail. 2005 Mar 2;7(2):261-7
pubmed: 15701476
J Psychosom Res. 2008 Mar;64(3):299-303
pubmed: 18291245
Psychosomatics. 1994 May-Jun;35(3):233-52
pubmed: 8036253
Aust N Z J Psychiatry. 2014 Nov;48(11):1048-58
pubmed: 25030807
J Psychosom Res. 2011 Feb;70(2):135-9
pubmed: 21262415
Psychother Psychosom Med Psychol. 2007 Feb;57(2):70-5
pubmed: 17211776
Aust N Z J Psychiatry. 2005 Sep;39(9):782-94
pubmed: 16168036
J Psychosom Res. 2015 Jan;78(1):25-33
pubmed: 25466985
BMC Health Serv Res. 2012 Aug 20;12:265
pubmed: 22906386
Psychother Psychosom Med Psychol. 2006 Sep-Oct;56(9-10):370-5
pubmed: 17031768
Br J Gen Pract. 2013 Apr;63(609):e274-82
pubmed: 23540484
PLoS One. 2014 Oct 06;9(10):e108969
pubmed: 25285790
PLoS One. 2018 Mar 13;13(3):e0194029
pubmed: 29534097
Psychosomatics. 1992 Fall;33(4):376-86
pubmed: 1461963
Medicine (Baltimore). 2020 Aug 21;99(34):e21650
pubmed: 32846776
PLoS One. 2020 May 20;15(5):e0233293
pubmed: 32433706
Eur J Intern Med. 2020 Mar;73:59-66
pubmed: 31791574
Swiss Med Wkly. 2021 Feb 05;151:w20405
pubmed: 33578431
BMC Health Serv Res. 2018 Jan 30;18(1):67
pubmed: 29382387
BMC Health Serv Res. 2018 Jun 27;18(1):498
pubmed: 29945622
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Psychother Psychosom. 2015;84(4):208-16
pubmed: 26022134
Gen Hosp Psychiatry. 2020 Sep - Oct;66:9-15
pubmed: 32592995
Psychother Psychosom Med Psychol. 2002 Jul;52(7):323-8
pubmed: 12181773
J Gen Intern Med. 2022 Sep;37(12):3070-3079
pubmed: 35048298
PLOS Digit Health. 2022 Apr 14;1(4):e0000017
pubmed: 36812502
Mayo Clin Proc Innov Qual Outcomes. 2020 Jan 14;4(1):40-49
pubmed: 32055770

Auteurs

Sophia Stahl-Toyota (S)

Department of General Internal Medicine and Psychosomatics, Medical University Hospital, Heidelberg, Germany.

Christoph Nikendei (C)

Department of General Internal Medicine and Psychosomatics, Medical University Hospital, Heidelberg, Germany.

Ede Nagy (E)

Department of General Internal Medicine and Psychosomatics, Medical University Hospital, Heidelberg, Germany.

Stefan Bönsel (S)

Department of Medicine Controlling, Medical University Hospital, Heidelberg, Germany.

Ivo Rollmann (I)

Department of General Internal Medicine and Psychosomatics, Medical University Hospital, Heidelberg, Germany.

Inga Unger (I)

Nursing Management, Department of Internal Medicine, Medical University Hospital, Heidelberg, Germany.

Julia Szendrödi (J)

Department of Endocrinology and Clinical Chemistry, Medical University Hospital, Heidelberg, Germany.

Norbert Frey (N)

Department of Cardiology, Angiology and Pneumology, Medical University Hospital, Heidelberg, Germany.

Patrick Michl (P)

Department of Gastroenterology, Hepatology and Infectious Diseases, Medical University Hospital, Heidelberg, Germany.

Carsten Müller-Tidow (C)

Department of Hematology, Oncology and Rheumatology, Medical University Hospital, Heidelberg, Germany.

Dirk Jäger (D)

Department of Medical Oncology, Medical University Hospital, National Center for Tumor Diseases, Heidelberg, Germany.

Hans-Christoph Friederich (HC)

Department of General Internal Medicine and Psychosomatics, Medical University Hospital, Heidelberg, Germany.

Achim Hochlehnert (A)

Department of Medicine Controlling, Medical University Hospital, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH